|
OA12625A
(en)
|
2001-06-22 |
2006-06-12 |
Pfizer Prod Inc |
Pharmaceutical compositions of adsorbates of amorphous drug.
|
|
BR0307515A
(pt)
|
2002-02-01 |
2004-12-07 |
Pfizer Prod Inc |
Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
|
|
DE60320940D1
(de)
|
2002-02-01 |
2008-06-26 |
Pfizer Prod Inc |
Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
|
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
|
CL2004001884A1
(es)
|
2003-08-04 |
2005-06-03 |
Pfizer Prod Inc |
Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
|
|
BRPI0413277A
(pt)
|
2003-08-04 |
2006-10-10 |
Pfizer Prod Inc |
composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
|
|
GT200600316A
(es)
|
2005-07-20 |
2007-04-02 |
|
Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
|
|
GT200600315A
(es)
|
2005-07-20 |
2007-03-19 |
|
Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
|
|
KR100767349B1
(ko)
|
2006-08-01 |
2007-10-17 |
삼천당제약주식회사 |
페노피브레이트를 함유하는 경구용 약제 조성물 및 그의제조방법
|
|
EP1923053A1
(en)
|
2006-09-27 |
2008-05-21 |
Novartis AG |
Pharmaceutical compositions comprising nilotinib or its salt
|
|
CN101185633A
(zh)
|
2007-12-14 |
2008-05-28 |
山东蓝金生物工程有限公司 |
一种治疗实体肿瘤的尼拉替尼缓释植入剂
|
|
CN101185627B
(zh)
|
2007-12-14 |
2011-04-20 |
山东蓝金生物工程有限公司 |
一种治疗实体肿瘤的尼罗替尼缓释植入剂
|
|
WO2009100176A2
(en)
|
2008-02-07 |
2009-08-13 |
Abbott Laboratories |
Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
|
|
CN101336890A
(zh)
|
2008-05-30 |
2009-01-07 |
济南基福医药科技有限公司 |
一种抗癌缓释凝胶注射剂
|
|
JO3634B1
(ar)
|
2009-11-17 |
2020-08-27 |
Novartis Ag |
طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
|
|
CA3152557A1
(en)
*
|
2010-10-29 |
2012-05-03 |
Abbvie Inc. |
Solid dispersions containing an apoptosis-inducing agent
|
|
IN2011CH01887A
(https=)
*
|
2011-06-02 |
2012-12-14 |
|
|
|
AR086913A1
(es)
|
2011-06-14 |
2014-01-29 |
Novartis Ag |
4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
|
|
CN102836159B
(zh)
|
2011-06-24 |
2014-12-10 |
南京圣和药业股份有限公司 |
达沙替尼分散体及其制备方法和其在片剂中的应用
|
|
US9301957B2
(en)
|
2011-11-14 |
2016-04-05 |
Novartis Ag |
Immediate release 4-methyl-3-4[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-YL)-3-(trifluoromethyl)phenyl] benzamide formulation
|
|
EP2802314B1
(en)
|
2012-01-13 |
2020-11-25 |
XSpray Microparticles AB |
A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
|
|
WO2014043618A1
(en)
|
2012-09-17 |
2014-03-20 |
Bind Therapeutics, Inc. |
Process for preparing therapeutic nanoparticles
|
|
JP2016522182A
(ja)
|
2013-04-24 |
2016-07-28 |
ドクター レディズ ラボラトリーズ リミテッド |
ニロチニブ塩酸塩の多形形態
|
|
EP2988729A1
(en)
|
2013-04-25 |
2016-03-02 |
Sun Pharmaceutical Industries Limited |
Pharmaceutical gastro-retentive solid oral dosage form of nilotinib
|
|
CN104367557A
(zh)
|
2013-08-12 |
2015-02-25 |
浙江九洲药业股份有限公司 |
无定型药物活性成分与pvp组合物的制备方法
|
|
PT107846B
(pt)
*
|
2014-08-01 |
2019-03-22 |
Hovione Farm S A |
Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
|
|
CN104274837B
(zh)
|
2014-09-18 |
2017-01-11 |
福格森（武汉）生物科技股份有限公司 |
一种尼洛替尼口服制剂
|
|
CA2964198C
(en)
|
2014-10-16 |
2023-03-14 |
Apotex Inc. |
Solid forms of nilotinib hydrochloride
|
|
WO2016097011A1
(en)
|
2014-12-19 |
2016-06-23 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous nilotinib
|
|
CN105983098B
(zh)
*
|
2015-01-30 |
2020-02-21 |
湖北生物医药产业技术研究院有限公司 |
用于提高难溶性的抗肿瘤药物生物利用度的固体组合物及其制备方法
|
|
EA036204B1
(ru)
|
2015-10-16 |
2020-10-14 |
Нобел Илач Санайи Ве Тиджарет А.Ш. |
Фармацевтические композиции нилотиниба гидрохлорида
|
|
CN106932522A
(zh)
*
|
2015-12-31 |
2017-07-07 |
上海奥博生物医药技术有限公司 |
一种尼罗替尼中杂质化合物i含量的测定方法
|
|
KR101770403B1
(ko)
|
2016-01-14 |
2017-08-23 |
중앙대학교 산학협력단 |
용해도가 개선된 셀레콕시브 고체분산체 및 이의 제조방법
|
|
WO2017149550A1
(en)
*
|
2016-03-02 |
2017-09-08 |
Msn Laboratories Private Limited |
Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
|
|
EP3429589B1
(en)
|
2016-03-17 |
2022-12-14 |
Sun Pharmaceutical Industries Ltd |
Pharmaceutical composition of nilotinib
|
|
CA3041134A1
(en)
|
2016-10-28 |
2018-05-03 |
Apotex Inc. |
Novel salts of nilotinib and crystalline forms thereof
|
|
CN107320460B
(zh)
|
2017-08-04 |
2020-11-03 |
北京化工大学 |
一种尼罗替尼口服纳米制剂及其制备方法
|
|
WO2020121326A1
(en)
|
2018-12-13 |
2020-06-18 |
Mylan Laboratories Limited |
Amorphous (rac)-tramadol.hcl-celecoxib (1:1)
|
|
US11103502B2
(en)
|
2019-01-10 |
2021-08-31 |
Slayback Pharma Llc |
Pharmaceutical compositions of lurasidone
|
|
CN113573712A
(zh)
*
|
2019-02-18 |
2021-10-29 |
斯莱班克制药有限责任公司 |
尼洛替尼的药物组合物
|
|
WO2020225738A1
(en)
|
2019-05-07 |
2020-11-12 |
Alembic Pharmaceuticals Limited |
Pharmaceutical composition comprising venetoclax
|
|
EP4096791A1
(en)
|
2020-01-31 |
2022-12-07 |
Nanocopoeia LLC |
Amorphous nilotinib microparticles and uses thereof
|
|
EP3903769A1
(en)
|
2020-04-30 |
2021-11-03 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Solid and liquisolid formulations of corallopyronin a
|
|
US20220378788A1
(en)
|
2020-04-30 |
2022-12-01 |
Nanocopoeia, Llc |
Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereof
|
|
WO2021222739A1
(en)
|
2020-04-30 |
2021-11-04 |
Nanocopoeia, Llc |
Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
|
|
JP2023540185A
(ja)
|
2020-09-03 |
2023-09-22 |
ニコベンチャーズ トレーディング リミテッド |
組成物及び方法
|
|
MX2023003556A
(es)
|
2020-09-29 |
2023-06-13 |
Shenzhen Pharmacin Co Ltd |
Composiciones farmaceuticas.
|
|
AU2023239642A1
(en)
|
2022-03-25 |
2024-11-07 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical compositions of protac compounds and uses thereof
|